查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836768

神經血管設備市場（按產品、適應症、技術、最終用戶和分銷管道）—2025-2032 年全球預測

Neurovascular Neurology Devices Market by Product, Indication, Technology, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經血管設備市場將成長 60 億美元，複合年成長率為 8.02%。

主要市場統計數據
基準年2024年 32.3億美元
預計2025年 35億美元
預測年份：2032年 60億美元
複合年成長率（%） 8.02%

神經血管設備的策略實施，重點在於臨床緊迫性、多學科照護途徑和影響結果的技術趨勢

神經血管器械正處於技術創新、臨床緊迫性和不斷發展的護理路徑的十字路口，需要醫療保健、投資和監管領域的相關人員清晰且基於臨床的認知來採用。本介紹將重點介紹微創治療和診斷影像的進步如何改變急性中風護理、動脈瘤管理和血管畸形治療。臨床醫生越來越依賴兼具改進機械性能和更佳輸送能力的精密器械，而影像解析度和程式引導系統的同步改進也推動了這一趨勢。

臨床情況是，腦血管意外的發病率和死亡率仍然很高，這給縮短治療時間、提高手術成功率和改善長期神經系統預後帶來了持續的壓力。為此，設備開發人員專注於提高部署的可靠性、減少術中併發症，並創新材料科學以調節血栓形成和癒合反應。同時，衛生系統正在重組其網路，以優先考慮快速分流、集中血栓切除中心，並在適當的情況下擴大門診手術的作用。

監管和報銷動態仍然是採用軌蹟的核心，核准越來越依賴穩健的臨床終點和對上市後監測的承諾。介入性神經放射科醫生、神經外科醫生和卒中神經科之間的合作正在加深，這種跨學科的合作正在加速設備的迭代改進和真實世界證據的生成。這些因素的共同作用，使得神經血管器械成為那些尋求對患者預後產生持久影響並創造長期價值的組織的策略重點。

設備工程、影像分析和護理服務重新設計如何重塑神經血管護理的臨床採用、採購和創新途徑

在儀器工程、數位診斷和醫療系統組織融合發展的推動下，神經血管介入領域正在經歷變革性變革。在設備層面，從純機械解決方案轉向整合平台的轉變正在加速。新型血流路徑導流結構和生物活性表面處理技術反映出人們更加重視透過更少的輔助手術實現動脈瘤的持久閉塞，而回收器和抽吸器設計的創新則優先考慮血栓截留和減少內皮損傷。同時，增強的成像和分析技術能夠更精確地表徵病變並進行手術規劃，從而支援針對特定解剖和病理亞型的設備迭代。

在營運方面，我們看到了明顯的轉變，即將某些程序分散到低危診中心，在這些中心，病人選擇和精簡的方案能夠實現安全且經濟高效的干涉。這種混合醫療模式的實現得益於針對門診使用而最佳化的設備設計和簡化的庫存管理。此外，臨床試驗設計也不斷發展，強調自適應方案和真實世界證據，從而能夠在保持方法學嚴謹性的同時，更快地實用化有前景的技術。

在宏觀面，供應鏈韌性和監管協調正在影響產品藍圖和打入市場策略。企業正在投資本地製造、戰略夥伴關係和基本契約，以應對報銷壓力和採購合理化。這些轉型並非漸進式的；它們將重塑競爭定位、臨床醫生的決策以及廣泛臨床應用的時間表。

評估美國新關稅對整個設備組合的採購、製造轉移和創新資金的累積營運和策略影響

2025年美國加徵關稅為參與全球神經血管器械生產和分銷的相關人員帶來了新的複雜性，其累積影響涵蓋採購、製造和研發投資決策。關稅帶來的成本壓力在跨境供應鏈中集中的零件和原料上最為明顯，例如特殊合金、導管軸和滲透性標記物。隨著這些投入成本的上漲，製造商面臨策略性選擇：吸收成本、重新分配利潤，還是將其轉嫁給下游經銷商和醫療保健系統。

因此，採購組織和醫院系統正在加快努力，實現供應商多元化，審查合約條款，並透過長期合約和在地採購安排確保價格的可預測性。對於醫療設備製造商而言，關稅將促使他們重組供應鏈，可能採取近岸生產、篩選合格的替代供應商以及盡可能加強垂直整合等措施。雖然這些應對措施可以減輕長期風險，但通常需要前期投資和延長的資格認定期，這會與研發資金產生競爭。

規模較小的創新企業尤其容易受到影響，因為不斷上漲的進口成本可能會限制它們在沒有策略聯盟的情況下擴大臨床試驗和商業化上市的能力。同時，擁有多元化製造地的大型現有企業可以利用其規模來規範價格波動，補償這樣做會減少原本可以用於產品開發和上市的資源。總體而言，關稅是重新評估國際產品系列的關稅補貼（CTC）的催化劑，並強調了韌性規劃、情境建模以及與付款方主動對話的重要性，以維護臨床醫生和患者的可及性。

將產品設計、臨床指徵、交付技術、護理環境和分銷策略聯繫起來的細分級洞察，以推動採用和差異化

細分分析揭示了臨床需求、設備力學和通路動態如何相互作用以形成採用模式和商業性優先順序。依產品類型，球囊血管成形術導管透過順應性和非順應性球囊技術進行區分。順應性球囊適用於精細的血管重塑，而當需要精確的管腔擴張時，非順應性球囊是首選。栓塞線圈有多種類型，包括裸線圈、塗層線圈和水凝膠線圈。每種亞型都在即時閉塞、組織整合和長期穩定性之間進行權衡，幫助臨床醫生選擇合適的線圈。可生物分解的流量轉向器對於尋求血管修復而又不想承受終生植入負擔的臨床醫生很有吸引力，而永久性流量轉向器仍然是某些複雜動脈瘤形態的預設選擇。神經血管支架製造為球囊擴張型或自擴張式，選擇取決於對徑向力、血管迷宮性和輸送限制的需求。血栓摘取支架系統（例如 Solitaire 和 Trevo 設計）因其血塊接合機制、輸送特性以及與吸痰輔助設備的兼容性而有所不同。

依適應症分析，動脈瘤封堵策略必須考慮動脈瘤的解剖結構與囊狀結構，而器械的選擇則受瘤頸形態和載瘤血管受累情況的影響。動靜脈畸形的治療需要不同的手術方法，著重於血管巢的建立和栓塞控制，而出血性中風的治療則優先考慮穩定止血和預防再出血。缺血性中風的治療分為前循環中風和後循環中風，解剖入路、側支循環和時間敏感性決定了器械的選擇和手術策略。

技術細分區分為化學血栓溶解、血流改道療法和機械血栓切除術。機械血栓切除術進一步細分為抽吸導管策略和血栓摘取支架，每種策略在血栓移除效率和與輔助器具的兼容性方面均具有互補優勢。最終使用者細分分為門診手術中心、醫院和專科診所。門診環境需要針對高效週轉和不太複雜的病例進行最佳化的設備，而醫院則維持大量庫存以用於緊急手術，專科診所優先考慮支持可重複手術和專門後續護理的設備。直銷和分銷商之間分銷管道的動態影響培訓、服務水準和定價透明度，直銷能夠提供更緊密的臨床支持，而分銷商提供更廣泛的地理覆蓋和庫存緩衝。總之，這些細分揭示了產品設計、臨床指徵、技術選擇、醫療環境和通路策略必須如何協調才能實現臨床影響和商業性成功。

美洲、歐洲、中東和非洲地區以及亞太地區的區域動態和臨床基礎設施差異將影響監管途徑、報銷優先順序和實施模式

區域動態反映了監管、提供者基礎設施和付款人行為的差異，正在塑造整個神經血管器械領域的臨床實踐和商業策略。在美洲，強大的中風護理系統和整合的醫院網路支援先進的血栓切除術和血流分流技術的快速應用。卓越的醫療中心和高手術量使得強化訓練計畫成為可能，並促進了真實世界證據的收集，從而進一步加速了器械的採用。該地區的採購環境通常強調捆綁式醫療經濟學和價值展示，鼓勵器材申辦方將臨床數據與健康經濟學敘述結合。

歐洲、中東和非洲由於各國監管途徑、報銷政策差異以及介入科醫生取得途徑的差異，呈現出差異性。在西歐，集中式衛生技術評估流程和強大的臨床註冊系統創造了優先考慮長期療效和成本效益的採取路徑。中東和非洲部分地區已開始投資提升神經介入能力，但勞動力分佈和基礎設施的差異限制了其採用，從而為可擴展的培訓和服務模式提供了有針對性的機會。

亞太地區擁有廣闊而多樣化的機遇，其特點是醫院快速擴張、三級卒中中心投資不斷增加以及本地製造業蓬勃發展。不同司法管轄區的監管時間表差異巨大，打入市場策略通常需要與區域經銷商和本地製造商合作。此外，人口結構趨勢和對卒中風險因素的日益關注正在推動對急性護理設備和慢性病管理解決方案的需求，而某些市場的價格敏感性則需要客製化產品系列和靈活的分銷模式。在所有地區，協調臨床證據產生和上市後監測實踐對於維持設備應用和持續改進仍然至關重要。

結合臨床證據、培訓計劃和供應鏈彈性的競爭定位和夥伴關係策略確保了干涉專家的持久偏好

神經血管器械領域的競爭動態取決於規模主導能力與敏捷創新之間的平衡。大型醫療科技公司憑藉其廣泛的臨床試驗網路、豐富的監管經驗以及一體化的服務產品，與大型機構保持持久的合作關係。為了贏得臨床偏好並向付款人展示其價值，這些新興企業正在推進差異化技術，例如新型生物可吸收血流轉向器、先進的聚合物塗層彈簧圈以及下一代抽吸導管。如果有令人信服的臨床數據支持，這些技術可以迅速引起臨床關注。

夥伴關係和策略聯盟正變得越來越普遍，這使得規模較小的創新者能夠獲得商業化的專業知識和規模，同時大型公司也能夠利用有針對性的能力來擴充其產品線。併購仍然是獲取新智慧財產權和擴大地域覆蓋範圍的重要機制，但監管的複雜性以及整合臨床教育工作的需求意味著交易必須經過仔細審查。

提供現場監考、混合模擬程序和術後分析的公司能夠提高臨床醫生的採用率，並縮短複雜設備的學習曲線。最後，積極關注供應鏈彈性、成本透明度和價值展示的公司，將為醫療系統克服預算和採購限制提供有利條件。這些策略行動共同創造了一個競爭環境，其中臨床證據、支持性基礎設施和供應鏈可靠性與設備性能同等重要。

為領導者提供一系列實用且具高影響力的建議，以協調臨床證據、供應鏈彈性、商業化模式和付款人參與，以實現持久成長

產業領導者應採取多管齊下的策略，將產品創新與商業嚴謹性、臨床參與度和供應鏈韌性結合。首先，優先考慮能夠產生有意義的以患者為中心的終點和可操作證據，並引起臨床醫生和付款人共鳴的臨床項目。其次，透過重新設計供應鏈策略、尋找替代供應商、考慮關鍵零件的近岸外包以及建立維持上市計畫的庫存緩衝，來降低關稅和零件集中度風險。

第三，我們將根據當地情況調整商業模式，將高銷售量中心的直銷與在覆蓋率和本地關係至關重要的市場與經銷商合作結合。第四，我們將投資臨床醫生培訓基礎設施，包括模擬、監考和數位決策支援，以縮短採用曲線並減少程序差異。第五，我們將儘早與付款人溝通，提供全面的價值檔案，清楚闡明臨床結果和健康經濟影響。

最後，整合數位化工具，增強手術規劃、後續跟進和設備性能監控，建構差異化服務層，從而支援高階定位。透過執行這些相互關聯的優先事項，產業領導者可以加速安全應用，應對成本壓力，並持續投資於下一代技術。

一種透明的混合方法研究途徑，結合臨床醫生訪談、專家小組和系統文獻綜合來檢驗臨床和商業性見解

基礎調查方法結合了嚴謹的一級研究和二級研究，以確保研究的相關性、有效性和對相關人員的實用性。一級研究包括對介入專家、醫院採購負責人和設備管理人員進行結構化訪談，以了解他們在設備選擇、操作偏好和應用障礙方面的現場觀點。此外，由中風和血管神經外科專家組成的專家專題研討會對這些訪談進行了補充，以檢驗臨床假設並解讀操作趨勢。二級研究則包括對同行評審出版物、臨床試驗註冊中心、監管文件和設備技術文獻進行系統性回顧，以對研究結果進行三角檢驗並揭示技術創新的軌跡。

數據合成透過將定性見解與客觀指標（例如器械核准歷史記錄、指南更新和已發表的程序結果）進行交叉驗證來實現。在適當情況下，進行了情境分析，以評估對政策變化和供應鏈中斷的敏感度。品管流程包括獨立編輯評審、臨床顧問檢驗以及概述納入標準、訪談方案和限制的調查方法檢驗。假設和證據來源的透明度支持了所提出見解的可信度，同時也認知到臨床實踐和政策環境正在不斷發展，需要持續監測。

簡潔的綜合強調了技術創新、證據產生和商業性實施之間的基本一致性，以將設備進步轉化為改善的患者結果。

總而言之，神經血管神經病學器械領域的特點是技術快速進步、醫療服務模式不斷發展，以及對供應鏈價值和韌性的日益重視。器材設計和影像處理的進步顯著提高了操作能力，但其永續應用取決於可靠的臨床證據、審慎的報銷策略以及整個醫療系統的營運準備。政策變革和貿易動態帶來了新的限制因素，需要透過多元化採購和策略夥伴關係關係來積極應對。

未來的成功將青睞那些將臨床創新與嚴謹的商業化相結合、投資於臨床醫生培訓和上市後證據、並採取尊重監管和支付方差異的靈活區域戰略的機構。將產品開發與可證明的療效和服務導向的主張提案結合，將使相關人員能夠應對定義該市場的臨床需求、經濟壓力和技術機會之間的複雜相互作用。持續關注真實世界的性能數據並與臨床醫生群體合作，對於將設備創新轉化為大規模改善的患者療效至關重要。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 機器人血栓切除系統與即時影像引導結合，實現精準血栓切除
  • 生物可吸收支架的出現旨在減少長期血管刺激並改善患者預後
  • 開發基於人工智慧的診斷平台，用於早期發現高風險患者的腦血管異常
  • 導管設計取得進展，採用親水塗層和靈活的遠端尖端，用於複雜的神經血管導航
  • 擴展遠距神經介入服務，以便在血管內手術期間實現遠距指導和諮詢

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章神經血管設備市場（按產品）

  • 球囊血管成形術導管
    • 順應性球囊
    • 不合規球囊
  • 栓塞線圈
    • 裸露線圈
    • 塗層卷材
    • 水凝膠線圈
  • 流量轉向器
    • 可生物分解的導流器
    • 永久流量轉向器
  • 神經血管支架
    • 球囊擴張型支架
    • 自動擴張型支架
  • 血栓摘取支架系統
    • 紙牌
    • 特雷沃

第9章神經血管設備市場（按適應症）

  • 動脈瘤閉塞
    • 梭形動脈瘤
    • 囊狀動脈瘤
  • 動靜脈畸形
  • 出血性中風
  • 缺血性中風
    • 前循環卒中
    • 後循環中風

第 10 章神經血管設備市場（按技術）

  • 化學溶栓
  • 流量轉換
  • 機械血栓切除術
    • 吸痰導管
    • 支架取栓器

第 11 章神經血管設備市場（依最終用戶）

  • 門診手術中心
  • 醫院
  • 專科診所

第 12 章神經血管設備市場（依通路）

  • 直銷
  • 經銷商

第 13 章。神經血管設備市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章神經血管設備市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按國家/地區分類的神經血管設備市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Medtronic plc
    • Stryker Corporation
    • Johnson & Johnson
    • Penumbra, Inc.
    • Terumo Corporation
    • MicroPort Scientific Corporation
    • Boston Scientific Corporation
    • MicroVention, Inc.
    • Cerenovus, LLC
    • Acandis GmbH
Product Code: MRR-036C5CF3B4E4

The Neurovascular Neurology Devices Market is projected to grow by USD 6.00 billion at a CAGR of 8.02% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.23 billion
Estimated Year [2025] USD 3.50 billion
Forecast Year [2032] USD 6.00 billion
CAGR (%) 8.02%

A strategic introduction to neurovascular devices emphasizing clinical urgency, multidisciplinary care pathways, and technological trends shaping procedural outcomes

Neurovascular neurology devices are at the intersection of technological innovation, clinical urgency, and evolving care pathways, demanding a clear, clinically informed introduction for stakeholders across healthcare, investment, and regulatory spheres. This introduction frames the current landscape by highlighting how advances in minimally invasive therapies and imaging have reshaped acute stroke care, aneurysm management, and the treatment of vascular malformations. Clinicians increasingly rely on precision devices that integrate refined mechanical properties with improved deliverability, and this trend is supported by parallel enhancements in imaging resolution and procedural guidance systems.

The clinical context is defined by persistently high morbidity and mortality associated with cerebrovascular events, which creates sustained pressure to improve time-to-treatment, procedural success rates, and long-term neurological outcomes. In response, device developers have focused on reliability of deployment, reduced intraprocedural complications, and materials science innovations that modulate thrombogenicity and healing responses. At the same time, health systems are realigning care networks to prioritize rapid triage, centralized thrombectomy-capable centers, and expanded roles for ambulatory procedural settings where appropriate.

Regulatory and reimbursement dynamics remain central to adoption trajectories, with approvals increasingly tied to robust clinical endpoints and post-market surveillance commitments. Collaboration among interventional neuroradiologists, neurosurgeons, and stroke neurologists is deepening, and this multidisciplinary engagement is accelerating iterative device improvements and real-world evidence generation. Taken together, these forces situate neurovascular devices as a strategic priority for organizations seeking durable impact on patient outcomes and long-term value creation.

How device engineering, imaging analytics, and care delivery redesign are together reshaping clinical adoption, procurement, and innovation pathways in neurovascular care

The landscape of neurovascular interventions is undergoing transformative shifts driven by convergent advances in device engineering, digital diagnostics, and health-system organization. At the device level, a move from purely mechanical solutions toward integrated platforms has accelerated: newer flow diversion constructs and bioactive surface treatments reflect an emphasis on durable aneurysm occlusion with fewer adjunctive procedures, while innovations in retriever and aspiration designs prioritize clot engagement and reduced endothelial trauma. Concurrently, imaging and analytics enhancements are enabling more accurate lesion characterization and procedural planning, which in turn supports device iteration that targets specific anatomical and pathological subtypes.

Operationally, there is an unmistakable shift toward decentralizing certain procedures to low-acuity settings where patient selection and streamlined protocols permit safe, cost-efficient interventions. This hybridization of care delivery models is being enabled by device designs optimized for outpatient use and simplified inventory management. In addition, clinical trial designs are evolving to emphasize adaptive protocols and real-world evidence, allowing faster translation of promising technologies while preserving methodological rigor.

On the macro front, supply chain resilience and regulatory harmonization are influencing product roadmaps and market entry strategies. Companies are investing in localized manufacturing, strategic partnerships, and value-based contracting to navigate reimbursement pressures and procurement rationalization. Taken together, these transformative shifts are not incremental; they reshape competitive positioning, clinician decision-making, and the timelines for broad clinical adoption.

Evaluating the cumulative operational and strategic consequences of new U.S. tariffs on procurement, manufacturing relocation, and innovation funding across device portfolios

The imposition of United States tariffs in 2025 has introduced a new layer of complexity for stakeholders engaged in the global production and distribution of neurovascular devices, with cumulative effects that extend across procurement, manufacturing, and R&D investment decisions. Tariff-driven cost pressure is most immediately apparent in components and raw materials that are concentrated in cross-border supply chains, including specialty alloys, catheter shafts, and radio-opaque markers. When these inputs become more expensive, manufacturers face strategic choices about absorbing costs, reallocating margins, or passing increases downstream to distributors and health systems.

Consequently, procurement organizations and hospital systems are reassessing supplier diversification and contract terms, accelerating efforts to secure price predictability through longer-term agreements or local sourcing arrangements. For device companies, the tariffs incentivize supply chain reconfiguration: nearshoring production, qualifying alternate suppliers, and increasing vertical integration where feasible. These responses can mitigate exposure over time but often require upfront capital and extended qualification timelines that compete with R&D allocations.

Smaller innovators are particularly vulnerable, as elevated import costs may constrain their ability to scale clinical trials and commercial launches without strategic partnerships. At the same time, larger incumbents with diversified manufacturing footprints can leverage scale to normalize pricing changes, albeit at the cost of redirecting resources that might otherwise fund product development or market expansion. In aggregate, the tariffs catalyze a re-evaluation of the cost-to-serve for international product portfolios, reinforcing the importance of resilience planning, scenario modeling, and proactive dialogue with payers to preserve access for clinicians and patients.

Segment-level insights connecting product design, clinical indications, delivery technologies, care settings, and distribution strategies to drive adoption and differentiation

A nuanced segmentation analysis reveals how clinical need, device mechanics, and channel dynamics interact to shape adoption patterns and commercial priorities. Within product categories, balloon angioplasty catheters are differentiated by compliant versus noncompliant balloon technologies, where compliant balloons are preferred for delicate vessel remodeling and noncompliant variants are favored when precise luminal expansion is required. Embolic coils vary across bare coils, coated coils, and hydrogel coils, and each subtype presents trade-offs between immediate occlusion, tissue integration, and long-term stability that inform clinician selection. Flow diverters divide into biodegradable and permanent devices; biodegradable flow diverters appeal to clinicians seeking vessel restoration without lifelong implant burden, while permanent flow diverters remain the default for certain complex aneurysm morphologies. Neurovascular stents are produced as balloon-expandable or self-expanding constructs, with choice contingent on radial force needs, vessel tortuosity, and delivery constraints. Stent retriever systems, exemplified by Solitaire and Trevo designs, are distinguished by clot engagement mechanics, deliverability profiles, and compatibility with aspiration adjuncts.

When analyzed by indication, aneurysm occlusion strategies must account for fusiform versus saccular anatomy, with device selection influenced by neck morphology and parent vessel involvement. Treatments for arteriovenous malformations require a different procedural mindset focused on nidus access and embolic control, while hemorrhagic stroke interventions prioritize hemostatic stabilization and prevention of rebleeding. Ischemic stroke management bifurcates into anterior circulation and posterior circulation strokes, where anatomical access, collateral circulation, and time sensitivity dictate device choice and procedural strategy.

Technological segmentation highlights distinctions between chemical thrombolysis, flow diversion, and mechanical thrombectomy. Mechanical thrombectomy further subdivides into aspiration catheter strategies and stent retrievers, each offering complementary strengths in clot retrieval efficiency and compatibility with adjunctive devices. End user segmentation shows divergent needs among ambulatory surgical centers, hospitals, and specialty clinics: ambulatory settings require devices optimized for streamlined turnover and lower complexity cases, hospitals maintain broad inventories for high-acuity procedures, and specialty clinics emphasize devices that support repeatable interventions and specialized follow-up care. Distribution channel dynamics between direct sales and distributors influence training, service levels, and pricing transparency, with direct sales enabling tighter clinical support and distributors offering broader geographic reach and inventory buffering. Collectively, these segmentation lenses illuminate how product design, clinical indication, technology choice, care setting, and channel strategy must be aligned to realize both clinical impact and commercial success.

Regional dynamics and clinical infrastructure differences that influence regulatory pathways, reimbursement priorities, and adoption models across Americas, EMEA, and Asia-Pacific

Regional dynamics shape both clinical practice and commercial strategy across the neurovascular device landscape, reflecting differences in regulation, provider infrastructure, and payer behavior. In the Americas, robust stroke systems of care and consolidated hospital networks support rapid adoption of advanced thrombectomy and flow diversion technologies; centers of excellence and high procedural volumes enable intensive training programs and foster real-world evidence collection that further accelerates device uptake. The purchasing environment in this region often emphasizes bundled care economics and value demonstration, prompting device sponsors to couple clinical data with health-economic narratives.

Europe, the Middle East & Africa exhibits heterogeneity driven by national regulatory pathways, variable reimbursement policies, and disparate access to interventionists. In Western Europe, centralized health technology assessment processes and strong clinical registries create a pathway for adoption that prioritizes long-term outcomes and cost-effectiveness. In parts of the Middle East and Africa, investment in neurointerventional capacity is emerging, but adoption is constrained by workforce distribution and infrastructure gaps, leading to targeted opportunities for scalable training and service models.

Asia-Pacific presents a large and diverse opportunity set characterized by rapid hospital expansion, increased investment in tertiary stroke centers, and local manufacturing growth. Regulatory timelines vary significantly across jurisdictions, and market entry strategies often require partnerships with regional distributors or local manufacturers. Furthermore, demographic trends and growing awareness of stroke risk factors are driving demand for both acute intervention devices and chronic management solutions, while price sensitivity in certain markets compels tailored product portfolios and flexible commercial arrangements. Across all regions, harmonizing clinical evidence generation and post-market surveillance practices remains critical to sustaining adoption and informing iterative device improvements.

Competitive positioning and partnership strategies that combine clinical evidence, training programs, and supply chain resilience to secure lasting preference among interventionists

Competitive dynamics across the neurovascular devices arena are defined by a balance between scale-driven capabilities and nimble innovation. Leading medtech firms leverage extensive clinical trial networks, broad regulatory experience, and integrated service offerings to maintain durable relationships with high-volume centers. These incumbents often invest in complementary technologies, training academies, and long-term post-market studies to entrench clinical preference and demonstrate value to payers. At the same time, agile emerging companies are advancing differentiated technologies-such as novel bioresorbable flow diverters, advanced polymer-coated coils, and next-generation aspiration catheters-that can rapidly capture clinical interest when supported by compelling procedural data.

Partnerships and strategic alliances are increasingly common, enabling smaller innovators to access commercialization expertise and scale while allowing larger firms to augment their pipelines with targeted capabilities. Mergers and acquisitions continue to be a key mechanism for acquiring novel intellectual property and expanding geographic reach, although transactions are subject to careful scrutiny given regulatory complexity and the need to integrate clinical education efforts.

Service and training models are also a point of differentiation; companies that provide hands-on proctoring, hybrid simulation programs, and post-procedural analytics strengthen clinician adoption and reduce the learning curve for complex devices. Finally, companies that proactively address supply chain resilience, cost transparency, and value demonstration position themselves favorably with health systems navigating budgetary and procurement constraints. Collectively, these strategic behaviors define a competitive environment where clinical evidence, support infrastructure, and supply-chain reliability are as consequential as device performance.

A pragmatic set of high-impact recommendations for leaders to align clinical evidence, supply chain resilience, commercialization models, and payer engagement for durable growth

Industry leaders should adopt a multi-pronged strategy that aligns product innovation with commercialization rigor, clinical engagement, and supply chain resilience. First, prioritize clinical programs that generate meaningful, patient-centric endpoints and pragmatic evidence that resonates with clinicians and payers; registries and pragmatic trials can complement randomized studies and facilitate faster, generalizable insights. Second, redesign supply chain strategies to mitigate tariff exposure and component concentration risks by qualifying alternate suppliers, considering nearshoring for critical components, and establishing inventory buffers that preserve launch timelines.

Third, tailor commercial models to regional contexts by combining direct sales in high-volume centers with distributor partnerships in markets where breadth of coverage and local relationships are paramount. Fourth, invest in clinician training infrastructures that include simulation, proctoring, and digital decision support to shorten adoption curves and reduce procedural variability. Fifth, engage payers early with comprehensive value dossiers that articulate both clinical outcomes and health economic impact; performance-based contracting and outcome guarantees can be considered where alignment is feasible.

Finally, embed digital tools that enhance procedural planning, follow-up, and device performance monitoring to create a differentiated service layer that supports premium positioning. By executing on these interconnected priorities, industry leaders can accelerate safe adoption, manage cost pressures, and sustain investment in next-generation technologies.

A transparent mixed-methods research approach combining clinician interviews, expert panels, and systematic literature synthesis to validate clinical and commercial insights

The underlying research methodology combines rigorous primary and secondary approaches to ensure validity, relevance, and practical utility for stakeholders. Primary research included structured interviews with interventionalists, hospital procurement leaders, and device executives to capture frontline perspectives on device selection, procedural preferences, and adoption barriers. These interviews were complemented by expert panel discussions with clinicians specializing in stroke and vascular neurosurgery to validate clinical assumptions and interpret procedural trends. Secondary research involved systematic review of peer-reviewed publications, clinical trial registries, regulatory filings, and technical device literature to triangulate findings and contextualize innovation trajectories.

Data synthesis relied on cross-validation of qualitative insights with objective indicators such as device approval histories, guideline updates, and published procedural outcomes. Where appropriate, scenario analysis was applied to assess sensitivity to policy changes and supply chain disruptions. Quality control processes included independent editorial review, clinical advisor validation, and methodological documentation that outlines inclusion criteria, interview protocols, and limitations. Transparency about assumptions and the sources of evidence underpins the confidence in the insights presented, while acknowledging that clinical practice and policy environments continue to evolve and warrant ongoing monitoring.

A concise synthesis emphasizing the imperative to align innovation, evidence generation, and commercial execution to translate device advances into improved patient outcomes

In conclusion, the neurovascular neurology device environment is characterized by rapid technological progress, evolving care delivery models, and intensified attention to value and resilience in supply chains. Advances in device design and imaging have materially improved procedural capabilities, but sustainable adoption depends on robust clinical evidence, sensible reimbursement strategies, and operational readiness across healthcare systems. Policy shifts and trade dynamics have introduced new constraints that require proactive mitigation through diversified sourcing and strategic partnerships.

Future success will favor organizations that integrate clinical innovation with disciplined commercialization, invest in clinician training and post-market evidence, and adopt flexible regional strategies that respect regulatory and payer heterogeneity. By aligning product development with demonstrable outcomes and service-oriented propositions, stakeholders can better navigate the complex interplay of clinical need, economic pressures, and technological opportunity that defines this market. Continued attention to real-world performance data and collaborative engagement with the clinician community will be crucial to translating device innovation into improved patient outcomes at scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of robot-assisted thrombectomy systems with real-time imaging guidance for precise clot retrieval
  • 5.2. Emergence of bioresorbable stents designed to reduce long-term vessel irritation and improve patient outcomes
  • 5.3. Development of AI-powered diagnostic platforms for early detection of cerebrovascular anomalies in high-risk patients
  • 5.4. Advancements in catheter design featuring hydrophilic coatings and distal-tip flexibility for complex neurovascular navigation
  • 5.5. Expansion of tele-neurointervention services enabling remote guidance and consultation during endovascular procedures

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Neurology Devices Market, by Product

  • 8.1. Balloon Angioplasty Catheters
    • 8.1.1. Compliant Balloons
    • 8.1.2. Noncompliant Balloons
  • 8.2. Embolic Coils
    • 8.2.1. Bare Coils
    • 8.2.2. Coated Coils
    • 8.2.3. Hydrogel Coils
  • 8.3. Flow Diverters
    • 8.3.1. Biodegradable Flow Diverters
    • 8.3.2. Permanent Flow Diverters
  • 8.4. Neurovascular Stents
    • 8.4.1. Balloon-Expandable Stents
    • 8.4.2. Self-Expanding Stents
  • 8.5. Stent Retriever Systems
    • 8.5.1. Solitaire
    • 8.5.2. Trevo

9. Neurovascular Neurology Devices Market, by Indication

  • 9.1. Aneurysm Occlusion
    • 9.1.1. Fusiform Aneurysm
    • 9.1.2. Saccular Aneurysm
  • 9.2. Arteriovenous Malformations
  • 9.3. Hemorrhagic Stroke
  • 9.4. Ischemic Stroke
    • 9.4.1. Anterior Circulation Stroke
    • 9.4.2. Posterior Circulation Stroke

10. Neurovascular Neurology Devices Market, by Technology

  • 10.1. Chemical Thrombolysis
  • 10.2. Flow Diversion
  • 10.3. Mechanical Thrombectomy
    • 10.3.1. Aspiration Catheters
    • 10.3.2. Stent Retrievers

11. Neurovascular Neurology Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Neurovascular Neurology Devices Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors

13. Neurovascular Neurology Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neurovascular Neurology Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neurovascular Neurology Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Medtronic plc
    • 16.3.2. Stryker Corporation
    • 16.3.3. Johnson & Johnson
    • 16.3.4. Penumbra, Inc.
    • 16.3.5. Terumo Corporation
    • 16.3.6. MicroPort Scientific Corporation
    • 16.3.7. Boston Scientific Corporation
    • 16.3.8. MicroVention, Inc.
    • 16.3.9. Cerenovus, LLC
    • 16.3.10. Acandis GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEUROVASCULAR NEUROLOGY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEUROVASCULAR NEUROLOGY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROVASCULAR NEUROLOGY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COMPLIANT BALLOONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NONCOMPLIANT BALLOONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BARE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COATED COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BIODEGRADABLE FLOW DIVERTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PERMANENT FLOW DIVERTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SOLITAIRE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TREVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FUSIFORM ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SACCULAR ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANTERIOR CIRCULATION STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY POSTERIOR CIRCULATION STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY CHEMICAL THROMBOLYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ANEURYSM OCCLUSION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY EMBOLIC COILS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY STENT RETRIEVER SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA NEUROVASCULAR NEUROLOGY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 280. NO